Safety of Prophylactic Intracameral Moxifloxacin Use in Cataract Surgery

Abstract

Purpose: To evaluate posterior and anterior segment safety of an intracameral injection of moxifloxacin as prophylaxis for endophthalmitis in cataract surgery. Methods: In this study, 60 eyes of 60 patients were included. In the first group, only 5% povidine iodine drop was administrated to 30 patients at the end of the surgery, while 30 patients were treated with intracameral moxifloxacin (250 mu g/0.050 mL) additionally in the second group. Visual acuity, intraocular pressure, corneal pachymetry, corneal clarity, and edema and retinal thickness were evaluated preoperatively and for day 3 postoperatively for each group and were compared. Results: Mean preoperative visual acuity was 0.7 +/- 0.9 LogMAR in both groups 1 and 2, while mean postoperative visual acuity was 0.05 +/- 1.00 LogMAR in both groups. Preoperative and postoperative intraocular pressure averaged 13.2 +/- 2.0 and 13.2 +/- 2.1 mmHg, respectively, in the first group, while preoperative and postoperative intraocular pressure was 14.9 +/- 2.1 and 14.3 +/- 2.0, respectively, in the second group. Preoperative and postoperative visual acuity changes and intraocular pressure changes were not significantly different between 2 groups. There was no single case of corneal edema. In the first group, preoperative pachymetry was 523 +/- 44 and postoperative pachmetry was 536 +/- 45 mu m, while in the second group preoperative pachymetry was 527 +/- 43 and postoperative pachymetry was 543 +/- 42 mu m. Preoperative and postoperative pachymetry changes were not significantly different between 2 groups. Mean preoperative macular thickness in the first group was 188 +/- 7.73 mu m, while it was measured as 189 +/- 7.75 mu m postoperatively. In the second group, mean preoperative macular thickness was 188 +/- 8.89 mu m, while it was 189 +/- 9.61 mu m postoperatively. Preoperative and postoperative optical coherence tomography (OCT) measure changes were not significantly different between the 2 groups. No study-related adverse events were noted. Conclusion: There was no increased safety risk associated with a 250 mu m/0.050 mL intracameral injection of moxifloxacin, which appears to be safe in the prophylaxis of endophthalmitis after cataract surgery.